The Healing Power of Botanical Therapeutics®
Herborium Group Launches Aggressive Social Media Marketing Strategy for AcnEase® Product Line 11/10 08:30 AM



SADDLE BROOK, N.J., Nov. 10, 2011 /PRNewswire/ --Herborium Group, Inc. (HBRM:$0.0017,$0.0000,0.00%) , (PK: HBRM) www.herborium.com, a Botanical Therapeutics™ company, announced today that it has retained the services of Extreme Media, a public relations firm specializing in Social Media, to launch the Company's social media marketing campaign for its proprietary acne treatment AcnEase®. This will be one of many steps the Company is taking to make a strong push in the $50 billion global market for acne treatment.
In light of the withdrawal by Hoffmann-La Roche Inc. from further manufacturing and distribution of Accutane® (isotretinoin), the leading treatment for severe acne that is presently a subject of a class action suit, Herborium (HBRM:$0.0017,$0.0000,0.00%) 's AcnEase is perfectly positioned for an exponential growth as it is the all-botanical ingredients based, safe and effective alternative for addressing the acne problems that affect close to 60 million individuals in the US.
Dr. Agnes P. Olszewski, Chairmen and CEO of Herborium (HBRM:$0.0017,$0.0000,0.00%) noted, "A social media strategy is a very cost effective marketing tool and will allow Herborium (HBRM:$0.0017,$0.0000,0.00%) to take advantage of the strong consumer trends to pursue natural health alternatives and self medication decisions. The use of social media to educate consumers and healthcare providers about the benefits of AcnEase is an important step in the Company's growth strategy. This key marketing strategy for brand building will be applied to other Herborium (HBRM:$0.0017,$0.0000,0.00%) products; including our unique all herbal ingredients based Women and Men Sexual Therapeutics."
"Since acne is both a disease and a social affliction, AcnEase bridges the healthcare and personal care (beauty) market making it an ideal candidate for a strategy using a social media platform and will serve as an effective tool to increase both our sales and market share," concluded Dr. Olszewski.
About AcnEase (www.acnease.com)
AcnEase® is a proprietary, all herbal, systemically acting botanical therapeutic® targeting the symptoms of acne in both females and males of all ages. Unlike many herbal products, AcnEase has been validated through clinical testing. The results demonstrated that approximately 95% of the patients with adolescent acne responded positively to AcnEase. In adults with hormonal or chronic acne the level of effectiveness was 85%. The overall positive response rate to AcnEase was 91%. To date, after 5 plus years on the market, Herborium (HBRM:$0.0017,$0.0000,0.00%) has registered a 95.5% consumer satisfaction rate for the AcnEase product.
About Herborium Group, Inc. (HBRM:$0.0017,$0.0000,0.00%)

interstate...

You might be right. Thanks. eom

Exactly. It's been happening lately, after action was taken. The pleasure is sinful.

Brilliant. Thanks for sharing your thinking. eom

Understood, thanks.

My post was in response to someone else, which is now deleted.

This ACTC forum... eom

Green yesterday!!!!

It's refreshing if we concentrate to ACT. Bad enough what's going on around the country.

Peace... Yes that is correct.

Point well taken, as the post emphasized. eom.

I'll credit Rabin to that to some degree. eom.

Posted by FJYOKOSK on another forum...

Scientific Reputation vs. short-term share value 42 minutes ago
This is in response to an email MrsMag copied from ICell...reportedly from Rabin, in which Rabin says he will not jeapordize ACTC's scientific reputation for short-term share value. Whether this response is truly from Rabin is unverified by myself, but if so (and I have no reason to believe otherwise), here is how I interpret this statement. And for note, I have a strong scientific research background and am familiar with submitting articles to scientific journals (and how frustrating it can truly be)...


Back in the summer there was a conference call, in which I believe Rabin had said they would expect to have their first reports out in mid-October.

So what went wrong...well, nothing except the usual slowness. We all saw how long the DSMB took to get the approval for injecting the 2nd and 3rd patients for each subgroup. And that was only after analyzing 2 patients' data.

From what I remember, Rabin mentioned that with positive data, they were looking at articles in scientific journals like Nature. For those not familiar with the process of submitting to such ELITE scientific journals, there are very specific criteria that must be met before the journal will accept the submission. All the statistics must be reviewed and formatted properly. There are word counts and margin restrictions...and we're not talking high school or college level adjustments, but REALLY fine-tuning the abstract, Methods, Data, Discussions, etc. AND, this must be done specifically to EACH scientific journals request. Remember that if there was significant efficacy, every prominent scientist, media haven, religious segments, lawyer...EVERYONE...will be combing through every single word of a GROUND-BREAKING experiment and downright miracle (again, if we already have efficacy). This is where I believe you can factor in Rabin's statement about not disrupting the scientific value in the face of short-term shareholder interest. My guess is that ACTC will try submitting to many of the elite scientific journals, but want the articles to all come out around the same time...and they will need multiple media responses and lawyers at the ready for the barrage that will come once word gets out.

Again, the DSMB approved the next injections = GOOD
The FDA trial website shows ongoing trials = GOOD
There are a billion bashers spending 24/7 on this board = GOOD (and weak hands are allowing more accumulation for us believers)
Rabin is 'surprised' at 'what we see' = GOOD (missing direct quote, but positive when you read between the lines).

So the negatives are this unfortunate onslaught, likely stemming from BigPharma supported hedge funds. I don't know how you fight that, but I'm not going to. I will hold my shares as long as I feel the company is not going backwards SCIENTIFICALLY. These fluctuations are just games played by the big boys, but with efficacy, the science wins out, and shareholders will have some sort of gains to smile about.

There will be a date of publication for these scientific publications. Again, I think they will all be around the same date (which can occur with online publications). No major journal will want to be left out. There will be a hurricane of activity, and hundreds of millions of shares will be traded on that day. Will you be long when it happens?

Just IMO.

Good luck to all longs!

I think you are right. Bought 200k at 1:37 pm at .002 and it was shown as a sale on the chart. Go figure.

Care to share the reason behind that. Thanks. eom.

Top Gun... I am not sure we can afford a "TOP GUN". Also, a so called top gun would like to be a CEO at ACT. Although' everything looks very good, nothing has been proven yet in human. The on going trial has yet to be completed and approved. Not knocking the approval to begin trial from FDA(which is paramount), all the patents and everything else.

Gary Rabin... I am sure he is trying his best what's already on his plate. Not to say. I'm impressed based solely to the pps declined. If he is not good for the job, well that is for the BOD's to act on. What I don't like was his compensation and maybe his dexterity for the job is not compatible to his background. He should have set an example to be prudent which I'm sure will put a very good impression to his team and most of all to the shareholders. amoo.

I hope the news will come early part of Nov. If it is like Avon/Mary Kay, I also hope it will be here in the US.

Volume is anemic. Looks like those who sold are not coming just yet. I wonder, is there another shoe to drop?

In 4hrs back to square one. What is Social Marketing... do you know. My sense, it's like Avom. If so I think it is great. m2c.

Fern Wood... That's very comforting to know. Thanks.

rumit,

It is an old article. Thanks. eom.

Is there a way to find out if management is selling. I'm sure, your point of view which is troubling is shared by many.

Very interesting. Thanks for sharing. eom.

When to buy and when to sale is a private decision. moo.

I'll hold until dec. and see what happens.

Production of sickle cell drugs’ll commence December –NEXIM DG

Monday, 03 October 2011

THE Managing Director, Nigeria Export and Import Bank, Mr Roberts Orya, has promised that the production of “NIPRISAN,” a sickle cell drug, will commence in the next 60 days.

Orya disclosed this in an interview with the News Agency of Nigeria (NAN) in Washington DC, United States (US).

“I believe that as soon as I get back to the country, we will sign the MoU (memorandum of understanding) and then we commence the process.

“Give and take, we should be looking at 45 to 60 days, we should commence the production of NIPRISAN by December,” he said.

Orya said the Minister of State for Health, Alhaji Mohammed Pate, has taken the production of the drug as his priority, adding that the delay in the commencement of its production was caused by some challenges among the stakeholders.

NAN reported that NEXIM had syndicated more than N700 million in loan with Diamond Bank and Bank PHB for the production of the drugs in the country.

“We have the highest exposure and that is why we are driving the process,” Orya told NAN in the interview.

It will be recalled that the Federal Government, two years ago, stopped the production of NIPRISAN, formerly known as “Nicosan,” due to issues bordering on finance.

Nicosan, which was discovered by the National Institute for Pharmaceutical Research and Development (NIPRD), was produced then by Xechem Nigeria Ltd.

The drug, produced with extracts from four botanical plants in Nigeria, does not cure sickle cell anaemia, but only manages to reduce the frequency of the ailment.

http://tribune.com.ng/index.php/news/29045-production-of-sickle-cell-drugsll-commence-december-nexim-dg

Any particular news you are expecting? eom

Thanks for sharing and of course your effort. eom.

The other side of the equation is that, all these
sells are being bought,... I would think. eom

Come to think of it, any comment/s from Monty. thanks.

A number of big buys. Anything out there. eom.

Anyone...
Can the company do anything to stop the pps from falling down.
With a good news, it goes down as well with no news. Very hard to understand. Does Mr. Rabin doing everything he needs to do to stop this downward trend? thanks

If you don't mind, share with us any response. Thanks.
That is a lot of dots to connect.

Same here. Hope this will stop the downward trend. eom

Looks like it's the norm... someone else is responsible. jmo.

City... Thanks for sharing. eom.

louisa...

Thanks for sharing. eom.

I used to have much more than that, but I was able to sell 9900,000
5mos ago(can not sell 10mil). Also, sold 5mil last dec. last year. I still have mils sh wanted to sell. All proceeds went to buy ACTC.

I wonder how these people sleep at night.

Thanks for your reply.

Paul...

Hbrm is dividend from ECGA, correct!. BTW, what is happening with that co.

Please post your answer on that board. thanks.

Anybody...

Any comment/s about the "Merger or Acquisition." Selling all assets. What happen to common sh. Are we out of luck, to say it mildly. Thanks

Ten weeks since the trial started.
Any comments! Thanks. eom.

rocky301...

Thanks for sharing. Lots of questions answered.

Wish you well and have full recovery.

Good post, however, if the October result is clean/very good, Rabin I hope will think about fast track for the rest/subsequent trials if that is possible m2c.

Thanks...